Oncolytics Biotech Inc T.ONC

Pfizer appoints chief oncology officer as new CSO

[Noteable]

November 20, 2024 - Chris Boshoff will take over the role of chief scientific officer and president of research and development as of January 1, 2025. He rises from his position as chief oncology officer and executive vice president to oversee Pfizer’s entire R&D organization across all therapeutics areas. Boshoff has been with Pfizer for 11 years, working on 24 medicines and biosimilars in over 30 indications, Pfizer said 

“Chris has a compelling vision for the future of R&D at Pfizer and deep knowledge of our entire pipeline and R&D organization that positions him well to succeed,” Pfizer CEO Albert Bourla said in a statement. “Under Chris’ leadership, oncology has become one of Pfizer’s most productive divisions and his continued supervision will ensure that we achieve our goal of being a global leader in oncology and other core therapeutic areas.”

https://www.biospace.com/business/pfizer-shakes-up-c-suite-elevating-cancer-chief-boshoff-to-cso

[Noteable]

Pfizer’s Oncology R&D organization will maintain its fully integrated structure with Roger Dansey, M.D. serving as Interim Chief Oncology Officer, reporting to Dr. Boshoff effective January 1, 2025. Dr. Dansey will assist Dr. Boshoff in selecting a permanent Chief Oncology Officer, after which time he will retire from Pfizer. He will also facilitate a smooth transition of his current

[Noteable]

Chris Boshoff is personally familiar working with ONCY and has Pfizer has developed the SC delivered PD-1 checkpoint inhibitor sasanlimab that can benefit from the addition of ONCY's IV delivered  pelareorep to synergistically boost the effectiveness of both drugs for use in multiple cancers.